Responses
Clinical/translational cancer immunotherapy
Original research
Neoadjuvant sintilimab and chemotherapy in patients with potentially resectable esophageal squamous cell carcinoma (KEEP-G 03): an open-label, single-arm, phase 2 trial
Compose a Response to This Article
Other responses
No responses have been published for this article.
